MTOR and breast carcinoma: Cai et al.[36]reported that overexpression of p-mTOR is associated with poor prognosis in early-stage breast carcinoma patients, with 5year survival rates of 32.7% and 56.4% for p-mTOR-positive and -negative patients, respectively.